EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

NCT00448305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: EndoTAG-1 + paclitaxel
DRUG: EndoTAG-1
DRUG: Paclitaxel

Sponsor

MediGene